Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Followed by 23-Valent Pneumococcal Polysaccharide Vaccine 6 Months Later, in At-Risk Adults 18–49 Years of Age (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors
Human Vaccines & Immunotherapeutics（2023）
Key words
Pneumococcal vaccine,V114,15-valent PCV,PCV13,PPSV23,at-risk adults
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined